Gene expression profiling predicts clinical outcome of prostate cancer
J. Clin. Invest. Gennadi V. Glinsky, et al. 113:913 doi:10.1172/JCI20032 [
Go to this article.]
Figure 1PAIs defined by the expression profile of the prostate cancer recurrence predictor signature 1 for 21 prostate carcinoma samples constituting a signature discovery (training) data set. Prostate tumor samples were taken from the patients at the time of surgery and subjected to a microarray gene expression analysis as described in Methods. Note that all samples derived from tumors of patients who subsequently manifested a biochemical relapse of disease have positive PAI values, whereas 12 of 13 samples obtained from patients who remained disease-free have negative PAI values. See text for details.
